Jada Bascom Foundation
All conditions

Leukemias

Philadelphia-positive B-cell acute lymphoblastic leukemia

Also called: Ph+ B-ALL · BCR-ABL1 B-ALL · Ph-positive ALL · acute lymphoblastic leukemia · Ph+ ALL · ALL · Philadelphia chromosome-positive B-ALL · B acute lymphoblastic leukaemia with BCR::ABL1 fusion

Classified by the World Health Organization as B-lymphoblastic leukaemia/lymphoma with BCR::ABL1 fusion.

What a donor has to do with this

For some people with this condition, a transplant using blood stem cells from an unrelated donor is part of the treatment guidelines. When a transplant is the right route and no one in the family matches, that donor comes from a registry. Not everyone with this condition has a transplant, and many never need one.

This is our reading of published transplant guidelines for this condition, not a measurement of how many people need a donor. Where a source actually counted donors, the figure and the people it counted are shown further down. Where none did, we say so rather than estimate.

What the evidence says

Who it affects
Typically diagnosed in adulthood, with BCR::ABL1 markedly more common as age rises and uncommon in childhood B-ALL. Source population/region/year: international adult ALL evidence synthesized in the EBMT Handbook, published 2024.
Treatments other than a transplant
Tyrosine-kinase inhibitor plus ALL therapy, blinatumomab-based regimens, and CD19 CAR-T in relapsed/refractory CD19-positive disease; post-CAR-T allo-HCT remains individualized
If a transplant is used, the cells come from
Allogeneic peripheral blood or bone marrow; cord blood and haploidentical grafts are alternatives when matched related/unrelated donors are unavailable; dominant source not reported in the opened disease-specific sources
How often the donor was unrelated
Not reported. No source we could read states this for this condition, so we do not give a number. An estimate here would be a guess dressed as evidence.

Where this gets complicated

Modern TKI/blinatumomab regimens may reduce CR1 transplant use in selected deep responders, but EBMT 2025 still states the aggregate standard; practice is evolving.

Written for transplant clinicians, not for patients. We quote it so you can see what the guidance actually says:
“allo-HCT represents the standard of care in Ph+ALL”

It describes what teams consider in general. It cannot say what applies to any one person. Read the source.

People with this condition need donors

Joining a registry is a cheek swab and a short health form. You are contacted only if you turn out to be a possible match for someone, and you can ask questions and decline before anything else happens.

Find your registry

Related conditions

Others in leukemias. They are genuinely different diseases with different treatments — the group name is not a diagnosis.

Where this came from